The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10322561" target="_blank" >RIV/00669806:_____/16:10322561 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00090185 RIV/00216208:11140/16:10322561

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy

Original language description

Abstract. Backround: The prognostic and predictive value of KRAS mutation in non-small cell lung cancer (NSCLC) is not well established. The present study is aimed at an elucidation of a role of KRAS mutation in prediction of outcome of patients with advanced NSCLC receiving second or third line chemotherapy. Patients and Methods: The outcome of 127 patients with advanced NSCLC who recieved pemetrexed or docetaxel at 2nd or 3rd line therapy was retrospectively analyzed. Results: Progression-free survival (PFS) was not significantly different between KRAS mutated and KRAS wild-type patients. The results were the same even if we have taken into account the specific types of KRAS mutations. Overall survival (OS) was significatnly longer for KRAS wild-type vs. KRAS mutated patients (16.1 vs.7.2 months). We observed shorter OS for G12C KRAS mutation vs. other KRAS mutation group of patients (median OS 10.3 vs 6.4 months). Conclusion: We observed that presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with 2nd or 3rd line pemetrexed or docetaxel.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FC - Pneumology

OECD FORD branch

—

Project

<a href="/en/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

36

Issue of the periodical within the volume

3

Country of publishing house

GR - GREECE

Number of pages

6

Pages from-to

1077-1082

UT code for WoS article

000375444200033

EID of the result in the Scopus database

2-s2.0-84991721108